PharmTech Drug Digest 11.20
News|Articles|November 23, 2016

Kymos Acquires Italian Firm Pharmaprogress

Spanish CRO, Kymos Pharma Services, announced that it has acquired Pharmaprogress, an Italian firm based in Ancona, specializing in contract research and analysis services.

Spanish CRO, Kymos Pharma Services, announced that it has acquired Pharmaprogress, an Italian firm based in Ancona, specializing in contract research and analysis services. Pharmaprogress has a 700-m2 analysis laboratory that is GMP authorized by the Italian Medicines Agency. The company is expected to deliver a turnover of EUR1 million in 2017.

Founded in 2001, Kymos has since worked on expanding internationally. With the acquisition of Pharmaprogress, Kymos estimates that 50% of its business volume will be generated outside Spain. Kymos’ main markets are Italy, France, Switzerland, Germany, and Portugal.

Source: Kymos


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.